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Abstract
Background: Rapid advances in scientific research have led to an increase in public awareness of genetic testing
and pharmacogenetics. Direct-to-consumer (DTC) genetic testing companies, such as 23andMe, allow consumers
to access their genetic information directly through an online service without the involvement of healthcare
professionals. Here, we evaluate the clinical relevance of pharmacogenetic tests reported by 23andMe in their
UK tests.
Methods: The research papers listed under each 23andMe report were evaluated, extracting information on effect
size, sample size and ethnicity. A wider literature search was performed to provide a fuller assessment of the
pharmacogenetic test and variants were matched to FDA recommendations. Additional evidence from CPIC
guidelines, PharmGKB, and Dutch Pharmacogenetics Working Group was reviewed to determine current clinical
practice. The value of the tests across ethnic groups was determined, including information on linkage
disequilibrium between the tested SNP and causal pharmacogenetic variant, where relevant.
Results: 23andMe offers 12 pharmacogenetic tests to their UK customers, some of which are in standard clinical
practice, and others which are less widely applied. The clinical validity and clinical utility varies extensively between
tests. The variants tested are likely to have different degrees of sensitivity due to different risk allele frequencies and
linkage disequilibrium patterns across populations. The clinical relevance depends on the ethnicity of the individual
and variability of pharmacogenetic markers. Further research is required to determine causal variants and provide
more complete assessment of drug response and side effects.
Conclusion: 23andMe reports provide some useful pharmacogenetics information, mirroring clinical tests that are
in standard use. Other tests are unspecific, providing limited guidance and may not be useful for patients without
professional interpretation. Nevertheless, DTC companies like 23andMe act as a powerful intermediate step to
integrate pharmacogenetic testing into clinical practice.
Background
Recent advances in technology have enabled comprehen-
sive characterization of the genetic component underlying
many complex diseases, traits, and responses to medica-
tion. This new information has enabled genetic testing to
become more widely available in healthcare, and can be
used to assess risk of inherited conditions and predict
response to medication. Such testing has the potential to
reduce drug-related adverse events, as well as to increase
the effectiveness of drugs by assessing how sensitive an
individual might be to a given pharmaceutical. Several
pharmacogenetic tests have become standard clinical
practice and others are supported by strong research evi-
dence. However, challenges exist in moving pharmacoge-
netic testing from a research endeavor to point-of-care
implementation.
Traditionally, genetic tests have been ordered in clinical
settings but direct-to-consumer (DTC) genetic testing
companies allow consumers to access their genetic infor-
mation through an online service without the intermedi-
ary of a healthcare professional. A 2012 review of online
companies offering pharmacogenetic testing identified
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eight companies providing at least one such test, either
DTC or through a healthcare practitioner [1]. 23andMe
was the most comprehensive DTC pharmacogenetic test-
ing company, and it remains active, although its portfolio
of pharmacogenetic tests has reduced substantially since
scrutiny by the FDA in 2013.
Pharmacogenetic testing is an interesting market for
DTC companies, since test results only become actionable
when a relevant drug is prescribed, which may be at the
point of testing or many years later. This contrasts with
genetic testing for disease variants where the increased –
or decreased – risk is of immediate relevance for the par-
ticipant. It may be cost-effective for individuals to undergo
pharmacogenetic testing once in their adult life, and store
the results, informing physicians whenever a new drug is
prescribed so any relevant gene-drug associations may be
checked. Such pre-emptive pharmacogenetic testing may
become routine practice, with data stored in the electronic
health record (EHR), but there are few current implemen-
tations of this [2]. The introduction of DTC genetic testing
has raised significant controversy amongst clinicians, aca-
demic researchers and the general public [3]. One of the
major concerns is the potential for misunderstanding and
misinterpretation of the test results, particularly when
pre- or post-test genetic counselling is not provided.
Here we study the pharmacogenetic tests offered by
23andMe to UK customers. 23andMe began offering
health-related tests to a UK market in December 2014,
when their US tests covered only ancestry testing,
following FDA concerns over their health tests. Cur-
rently, 23andMe provides reports on over 100 health
conditions and traits for UK customers. These reports
include (1) recessive inherited variants for conditions
such as cystic fibrosis and beta-thalassaemia, (2) dom-
inantly inherited genetic risk factors like variants in the
BRCA1 and BRCA2 genes, (3) drug response tests like
abacavir hypersensitivity and warfarin sensitivity and
(3) prediction of traits such as hair colour and earwax
type. 23andMe genotypes consumer’s DNA on the Illu-
mina HumanOmniExpress-24 format chip, with more
than 715,000 single nucleotide polymorphisms (SNPs),
together with custom content specific for their tests
(https://www.23andme.com/en-gb/health/; accessed 3rd
November, 2016). Consumer reports list each relevant
genotype together with a summary, and further infor-
mation on the test. 23andMe’s criteria [4] for including
a genetic test in its portfolio are that the drug response
tests are eligible if there are either existing clinical practice
guidelines provided by the Clinical Pharmacogenetics
Implementation Consortium (CPIC) and other clinical or-
ganisations, or if information from regulatory agencies or
in drug labels “acknowledges the impact of the genetic
marker on drug response”. 23andMe regards pharmacoge-
netic tests as potentially eligible if “there is meaningful
interpretation of a positive result”, and at least three scien-
tific research papers identify consistent clinical effects of
the marker tested [4].
23andMe currently provides reports on 12 pharmaco-
genetic tests for UK customers. Here, we evaluate the
extent to which these tests 1) represent the latest scien-
tific and clinical literature, 2) reflect recommendations
from the U.S. FDA and CPIC, and 3) are applicable
across different ethnic groups.
Methods
Data sources and search strategy
Each test within the Drug Response section of
23andMe UK genetic testing report was reviewed
(https://www.23andme.com/en-gb/health/reports). For
all 12 pharmacogenetic tests, the 23andMe website pro-
vides details of 1) the drug, disorder and variant(s) rele-
vant for the pharmacogenetic test, 2) possible outcomes
by genotype, 3) interpretation of test results, and 4) aca-
demic papers reporting the pharmacogenetic association.
Full technical information on the SNPs used to determine
test results are given, enabling each test to be assessed
fully.
The research papers listed under each 23andMe re-
port were evaluated, extracting information on effect
size, sample size and ethnicity. A wider literature search
was performed using PubMed and EMBASE assess the
pharmacogenetic test fully. The variants reported by
23andMe were matched to the FDA Table of Pharmaco-
genomic Biomarkers in Drug Labelling [5]. Additional
evidence from CPIC guidelines, [6] PharmGKB, [7] and
Dutch Pharmacogenetics Working Group (DPWG) [8]
was reviewed to determine current clinical practice.
SNP allele frequencies and linkage disequilbrium (LD)
between SNPs were determined using the 1000 genomes
project data through SNAP (http://archive.broadinstitu
te.org/mpg/snap/) and LDlink (https://analysistools.nci.
nih.gov/LDlink/) [9–11].
Results
Assessment of 23andMe Pharmacogenetic tests
23andMe provides pharmacogenetic reports for re-
sponse to 12 drugs, which are listed in Table 1, together
with the specific variants tested, the implicated gene,
the phenotype tested for (adverse drug reaction (ADR),
efficacy, dosage adjustment), and the FDA recommen-
dation. The reports are from diverse clinical areas and
drugs. Five reports are for variants in the cytochrome
P450 genes CYP2C19 and CYP2C9, which affect both
drug efficacy and adverse events. Genotypes are classi-
fied by metaboliser level and CPIC guidelines for dose
adjustment or recommendations for a different drug
are given. The remaining seven reports are for non-
cytochrome P450 drug toxicity and adverse events, such
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as abacavir hypersensitivity reactions which are associated
with HLA-B*57:01. All reports are for variants in a single
gene, except for warfarin which combines genotypes from
three SNPs in CYP2C9 and VKORC1. The report for
acetaldehyde toxicity, leading to increased risk of
oesophageal squamous cell carcinoma in people of
East Asian ancestry, is a curious entry in the list,
since the toxicity arises from a breakdown of alcohol,
a recreational drug, and not a pharmaceutical com-
pound as in the other 11 tests.
The FDA considers that pharmacogenetic tests for five
of the 12 drugs provide actionable results (fluorouracil,
peginterferon alpha, phenytoin, pseuodocholinesterase
deficiency and warfarin); genetic testing is required for
Table 1 Pharmacogenetic tests provided by 23andMe
Drugs Gene Variant SNP Purpose of test FDA/PharmGKB
Guidancea
Guidelinesb
Abacavir HLA-B *57:01 rs2395029 Hypersensitivity reactions Genetic testing required
CPIC, DPWG
CPIC, DPWG
Acetaldehyde ALDH2 *2 rs671 Toxicity and risk of oesophageal squamous cell
carcinoma
No recommendation -
Clopidogrel (Plavix®) CYP2C19 *2 rs4244285 Efficacy and ADRs Genetic
testing recommendation
CPIC, DPWG
*3 rs4986893
*4 rs28399504
*8 rs41291556
*17 rs12248560
Fluorouracil (Adrucil®) DPYD *2A rs3918290 Toxicity and ADRs Actionable PGx CPIC, DPWG
Peginterferon alpha
(PEG-IFN-alpha) &
ribavirin (RBV)
19q13
region
rs8099917 Hepatitis C treatment failure Actionable PGx CPIC
Phenytoin CYP2C9 *2 rs1799853 Sensitivity and Dosage adjustment Actionable PGx CPIC, DPWG
*3 rs1057910
Proton Pump Inhibitor
(PPI)
CYP2C19 *2 rs4244285 Efficacy and Dosage adjustment Informative PGx DPWG
*3 rs4986893
*4 rs28399504
*8 rs41291556
*17 rs12248560
Pseudocholinesterase BCHE F1 rs28933389 ADR - extended paralysis and apnoea Actionable PGx -
Deficiency F2 rs28933390
A rs1799807
Simvastatin SLCO1B1 *5 rs4149056 ADR - Myopathy No recommendation CPIC
Sulfonylurea CYP2C9 *2 rs1799853 Efficacy and Dosage adjustment No recommendation DPWG
*3 rs1057910
Thiopurine
Methyltransferase
TPMT c.460G > A,
*3B
rs1800460 Toxicity and ADRs Genetic
testing recommended
CPIC, DPWG
c.238G > C,
*2
rs1800462
c.719A > G,
*3C
rs1142345
Warfarin CYP2C9 *2 rs1799853 Efficacy and Dosage adjustment Actionable PGx CPIC
*3 rs1057910
VKORC1 rs9923231
aPharmGKB evaluated the pharmacogenetic (PGx) information provided by U.S. FDA approved drug labels, and assigned each test with a level of
recommendation according to the level of clinical evidence, [7] The levels begin from genetic testing required, genetic test recommended,
Actionable PGx to Informative PGx.
b: Guidelines from https://www.pharmgkb.org/view/dosing-guidelines.do published by the Clinical Pharmacogenetics Implementation Consortium
(CPIC) or the Royal Dutch Association for the Advancement of Pharmacy - Pharmacogenetics Working Group (DPWG)
*used to indicate that these values represent a given variant in the literature
Lu et al. BMC Medical Genomics  (2017) 10:47 Page 3 of 8
one (abacavir); recommended in two (clopidogrel and
thiopurine methyltransferase); one provides informative
results (proton pump inhibitor) and the remaining
three tests have no FDA recommendations (acetaldehyde,
simvastatin, sulfonylurea).
For most drugs, 23andMe tests the variants listed by
the FDA, but some differences exist. For phenytoin,
23andMe reports on drug sensitivity from CYP2C9*2
and *3 variants, but the U.S. FDA additionally lists
pharmacogenetic information on HLA-B*15:02, which
confers increased risk of life threatening hypersensivity
reactions like Stevens-Johnson syndrome (SJS) and
toxic epidermal necrolysis (TEN) [12]. CPIC guidelines
strongly recommend alternative treatments for patients
with HLA-B*15:02 positive status, [13] but 23andMe
does not report on HLA-B*15:02.
Differences between ethnicities
Many pharmacogenetic variants have frequencies that
vary substantially by ethnicity, and different patterns of
LD in associated regions, meaning that the relevance
and interpretation of tests is not homogeneous across
populations. For example, common genetic polymor-
phisms in CYP2C19 and CYP2C9 alter ability to metab-
olise drugs [14]. Individuals with CYP2C19*2, *3, *4, *8
and CYP2C9*2, *3 polymorphisms may be poor metaboli-
sers and may require dose reductions or an alternative
drug. The frequency of CYP2C19 poor metaboliser geno-
types is highest in individuals of East Asian ancestry (14%),
and is much lower in those of African ancestry (4%) or
European ancestry (2%) [15]. Conversely, CYP2C9*2 and *3
variants are common in European populations, with fre-
quencies of approximately 14% and 8% respectively. These
variants have lower frequency in African and East Asian
populations [13].
Pharmacogenetic testing for abacavir hypersensitivity
is well-established, with the drug label stating “All pa-
tients should be screened for the HLA-B*57:01 allele
prior to initiating therapy” [16]. Two large studies,
PREDICT-1 and SHAPE, have assessed the clinical util-
ity of this test (Table 1) [17, 18]. The studies confirmed
strong association between HLA-B*57:01 carrier status
and immunologically confirmed hypersensitivity reac-
tions, with sensitivity of 100% and specificity of >96%
in both European and African ancestries. 23andMe re-
ports test results based on SNP rs2395029, which is in
strong linkage disequilibrium with HLA-B*57:01. How-
ever, rare recombination events occur in some populations
[19] and there is incomplete LD between rs2395029 and
HLA-B*57:01: [20–22] 23andMe report rs2395029 hetero-
zygotes as having a 94% chance of carrying HLA-B*57:01.
In addition, little is known about the predictive value of
the SNP-based test in non-European populations. The
rs2395029-G allele is extremely rare in the African
population (~0%), and is only present in 1% of the East
Asian population. LD between HLA-B*57:01 and
rs2395029 varies by population, with perfect LD in Han
Chinese and Tamil Indians, but lower in Southeast Asian
Malays (r2 = 0.75). These SNP test results should therefore
be interpreted with caution, particularly in non-European
populations.
In peginterferon alpha (PEG-IFN-alpha) and ribavirin
(RBV) combined therapy for the chronic infection of
hepatitis C virus (HCV), 25–40% of patients fail to
respond. Genome-wide association studies identified a
significant association of rs8099917 with treatment
response, with the G allele increasing risk of failure to
response. Carriers of the rs8099917 TT genotype have a
2–3 fold increased chance of responding to therapy
[23]. A second SNP rs12979860, not reported by
23andMe, may have better predictive value in some
populations [24]. 23andMe reports only rs8099917,
stating that “because all of these SNPs are so closely
linked to each other, they are all probably representing
the same effect” [25]. However, the allele frequencies and
linkage disequilibrium between these variants differ across
populations (Table 2), so while these SNPs are in strong
LD in East Asian populations, the LD is much weaker in
African populations. The validity of this test may therefore
depend on ethnicity of the 23andMe customer, although it
is likely that neither SNP is the causal variant.
Frequencies of the rs9923231 T allele, which increases
sensitivity to Warfarin, vary across ethnicities. In 1000
Genomes phase 3 data, [9] the frequency is highest in
Europeans (39%), and the T allele is much rarer in South
Asians (15%), East Asians (12%), and Africans (5%).
For acetaldehyde toxicity, the ALDH2*2 (rs671, G > A)
variant is mainly found in East Asians and is rare in
other ancestries.
For 5-FU toxicity, the frequency of DPYD*2A is low
in all populations. It is almost non-existent in African-
American and Japanese populations, and has frequency
of 0.91% and 0.47% in Dutch and German populations
respectively [26].
For Simvastatin-induced myopathy, the frequency of
the minor allele of rs4149056 is highest in European and
Asian ancestries, with very low frequencies in African
populations [27]. 23andMe genotyping captures four of
the five non-functional alleles which reduce TPMT
Table 2 Population genetics of SNPs rs8099917 and rs12979860,
both associated with response to hepatitis C treatment
Population rs8099917 T/G MAF G rs12979860 C/T MAF T D' r2
European 0.17 0.31 0.97 0.43
East Asian 0.08 0.08 0.99 0.92
African 0.04 0.67 1.00 0.02
Minor allele frequencies (MAF) calculated using 1000 Genomes data; LD
parameters calculated using LDlink [9, 10]
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activity. The frequency of the functional *1 allele ranges
from 0.925 in Mexicans to 0.983 in Asians18 with fre-
quencies of the non-functional markers also varying by
ethnicity. The other non-functional alleles are not tested
for by 23andMe, but have a frequency of <0.1% in all
populations tested [28].
Limitations of 23andMe pharmacogenetic tests
For a number of the pharmacogenetic tests performed
by 23andMe, the most recent literature has additional
information on associations, making 23andMe’s tests
incomplete in their assessment of ADRs or efficacy.
For 5-FU, 23andMe tests only for the *2A variant, but
as 23andMe state on their website, further variants in
the gene are associated with 5-FU toxicity. For example,
recent studies have shown that DPYD*13, rs67376798,
c.1679 T > G and c.1236G > A/HapB3 are also associated
with 5-FU toxicity [28–30].
For pseudocholinesterase deficiency, 23andMe provides
reports on three variants, fluorine resistant 1 (F1), fluorine
resistant 2 (F2) and dibucaine resistant mutation (A). Other
mutations in BCHE with similar effect are not reported by
23andMe, such as K-variant, silent-1, silent-2 and silent-7
[31]. The protocol for selecting the specific variants to be
tested by 23andMe is not described and only two citations
are listed for this particular drug response, and which does
not meet their selection criteria [4].
For acetaldehyde toxicity, 23andMe reports on rs671,
which is mainly present in East Asians. An additional
variant rs1229984, A > G in ADH1B, increases risk of
oesophageal squamous cell carcinoma and is present in
multi-ethnic populations. Cui R et al. (2009) found that
the combination of ALDH2*2 and ADH1B variants with
smoking and drinking significantly increases the risk of
oesophageal squamous cell cancer 189-fold [32].
Assessing variation in TPMT is difficult and 23andMe
states that their current technology cannot distinguish
between the genetic changes in the same or different
copies of the TPMT gene. For example, it is not possible
to differentiate between one copy of *3A (reduced function)
and copies of *3B and *3C on different chromosomes (no
function). Although it is rare to carry both *3B and *3C
variants, incorrect interpretation of test results could lead
to dosing errors.
Discussion
Adverse events from drug hypersensitivity currently
place a large burden on healthcare costs and preventable
adverse drug events could cost the UK NHS up to £2.5
billion per year [33]. Some of these events are associated
with genetic factors, and so may be preventable through
pharmacogenetic testing. DTC pharmacogenetic testing
may have a role to play in either raising awareness of
pharmacogenetic testing, or providing customers with
preliminary information, which could be followed up
with healthcare professionals. However, these benefits
need to be balanced with the risks involved in providing
medical information that is not communicated through
a healthcare professional.
The reports provided by 23andMe to UK customers
highlight the challenges of pharmacogenetic testing, some
of which are unique to a SNP-based genotyping platform
as used by the DTC company, others of which are applic-
able to any technology, and any method of delivery. We
compared the 12 reports provided by 23andMe with
recommendations from the FDA and CPIC, finding sev-
eral differences between the two sources. 23andMe report
on some pharmacogenetic tests for which FDA provided
no recommendation (simvastatin, sulfonylurea and acetal-
dehyde); these tests are supported by research publications
and therefore (mostly) meet the selection criteria specified
by 23andMe. Not all pharmacogenetic tests with FDA
recommendations or CPIC guidelines are reported by
23andMe. Some omissions may be due to difficulties in
tagging the relevant pharmacogenetic variant. For ex-
ample, 21% (44/204) of the tests in the FDA Table of
Pharmacogenomic Biomarkers in Drug Labelling are
for CYP2D6 alleles. These cannot be assessed fully with
a genome-wide genotyping chip due to gene deletions
and sequence similarity with pseudogenes, and this may
explain the lack of CYP2D6 tests in 23andMe’s portfo-
lio. Some tests provided by 23andMe provide an incom-
plete assessment of risk variants within the target genes
(DPYD, ADH1B). Similarly, for phenytoin, 23andMe
assesses CYP2C9 variation, while the FDA’s table lists
tests for CYP2C9, CYP2C19 and HLA-B*15:02, with CPIC
providing guidelines for joint tests across CYP2C9 and
HLA-B*15:02. This omission is potentially serious since
HLA-B*15:02 carriers are at increased risk of SJS/PTEN,
and use of phenytoin in not recommended. Similarly,
carbamazepine-induced SJS/PTEN occurs in HLA-B*15:02
carriers. This variant is not reported by 23andMe, although
it is particularly relevant in East Asians where HLA-B*15:02
frequency is highest. Two SNPs in strong LD with HLA-
B*15:02 have been identified. A sample of 45 Han Chinese
from Beijing, China showed r2 = 1 with rs3909184 and
rs2844682, [34] but LD with rs3909184 was much weaker
in an Asian Pacific Islander population (sensitivity 32%; no
r2 value given). These population-level differences in LD
between HLA alleles and tagging SNPs make it difficult
to implement a pharmacogenetic test using only SNP data
from genotyping arrays, particularly in a DTC setting
which does not allow for subtleties in test interpretation.
This highlights the point that fully comprehensive phar-
macogenetic testing would require a combination of SNP
genotyping or sequencing, plus HLA serotyping.
For drug metabolising enzymes, 23andMe provide
reports on CYP2C19 for clopidogrel and proton pump
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inhibitors, but not for other drugs such as the widely
prescribed selective serotonin reuptake inhibitor anti-
depressants (SSRIs). CYP2C19 tests are listed on the
FDA table for SSRIs, and are available in a commercial
test by AssureX [35]. Guidelines for CYP2C19 pharma-
cogenetic tests are provided by CPIC (8 drugs) and the
Dutch Working Group (12 drugs), each of which in-
cludes the test provided by 23andMe.
One of the challenges in pharmacogenetics is the diverse
allele frequencies across populations. Different allele
frequencies may make the test only relevant in a single
population, as in testing for phenytoin and HLA-B*15:02
which is mainly found in Asian populations. Differing
allele frequencies for the causal variant does not affect
interpretation of the pharmacogenetic test result, but dif-
ferent linkage disequilibrium may invalidate interpretation
of a tagging SNP, as seen with rs8099917 and Hepatitis-C
treatment response. Without further work refining causal
SNPs at such loci, it is probable that pharmacogenetic
tests will provide different degrees of sensitivity across
ethnicities.
We have focused on DTC company, 23andMe, since
they are the largest provider in this market, and are com-
mendably open about the exact SNPs genotyped, and the
reports generated for each pharmacogenetic test – there-
fore enabling scrutiny of the service offered. These phar-
macogenetic reports are available to 23andMe customers
in the UK, Canada and some EU countries, but are not
currently provided to US customers. A 2012 review of
DTC pharmacogenetic testing companies, identified eight
companies that provided at least one pharmacogenetic
test [1]. Some of the companies surveyed require tests to
be ordered through a clinican (Genelex, Pathway genom-
ics), or are no longer in the market (Navigenics). Genepla-
net now provides DTC pharmacogenetics for six drugs or
drug classes (clopidogrel, metformin, omeprazole, peri-
ndopril, statins, warfarin), and Theranostics for two drugs
(clopidogrel, statins) but neither company gives detailed
information on the tests or reported outcomes and so are
not included here.
DTC pharmacogenetic testing has the potential to bene-
fit patients by educating individuals about genetics and
providing preliminary information that patients could
follow up with a medical professional. 23andMe’s public
website and customer reports make clear that they do not
provide a medical service and that the report is not a diag-
nostic test. Reports give risks (%) of an adverse event, and
general comments such as ‘may benefit from a different
dose’; they instruct customers to “consult with a health-
care provider about … appropriate next steps”, and not to
“make any changes to any current treatment without
first consulting a healthcare provider”. For each report,
23andMe provides detailed information about the test
performed, the evidence for gene-drug association, and
the implications of test results. In addition to clinical-
related information, full SNP genotypes are returned.
Pharmacogenetics is a particularly relevant focus for
DTC testing since the test has value throughout life,
and need be performed only once. This makes imple-
mentation of a pre-emptive pharmacogenetic testing
panel potentially cost-effective, since the results can be
interrogated when any new drug is prescribed.
1. The service offered by 23andMe has several
important limitations, and for the service offered
to be more effective, we would recommend a
number of changes, such as better consideration
and documentation of differences across ancestry.
For example, the literature shows substantial
differences in sensitivity and specificity of tests for
Hepatitis-C treatment response between ancestries.
This should be fully reported by 23andMe to ensure
all test users understand the ancestry-specific
limitations of testing. In the absence of research
linking the tested SNP to the response in a given
consumer’s ethnicity, this limitation should be
communicated clearly.
2. Better mechanisms should be in place to ensure
that tests reflect the latest science. Pharmacogenetic
research can move quickly, and producing out-of-
date or incomplete reports raises ethical questions.
3. More consideration of what tests should be reported.
Many 23andMe customers will not be knowledgeable
about the relative importance of the different tests,
and reporting tests that are not supported by the FDA
or other guidelines could cause unnecessary concern
or anxiety for customers.
Sequencing technologies may be required to achieve
these aims, as the current genotyping arrays do not al-
ways offer the variants required to perform effective
testing, and would enable a wider range of important
drug metabolising enzyme variation to be detected [36].
In addition, rare variants not identified in the literature
will continue to provide challenges to pharmacogenetic
testing on a large scale, and reduce the specificity of
tests performed.
Conclusions
Pharmacogenetic testing is likely to become a routine
part of clinical practice in the future. As it stands, the
DTC service offered by 23andMe has limitations but
has a role to play in familiarising people with genetics
and raising awareness. In particular, there are chal-
lenges in providing a service across all ancestry groups
when research to date has not fully resolved the causal
variants at associated loci.
Lu et al. BMC Medical Genomics  (2017) 10:47 Page 6 of 8
Abbreviations
CPIC: Clinical Pharmacogenetics Implementation Consortium; DPWG: Dutch
Pharmacogenetics Working Group; DTC: Direct-to-consumer; FDA: United
States Food & Drug Administration; LD: Linkage disequilibrium
Acknowledgements
None.
Funding
This paper represents independent research funded by the National Institute
for Health Research (NIHR) Biomedical Research Centre at South London and
Maudsley NHS Foundation Trust and King’s College London and by the NIHR
Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust
and King’s College London. The views expressed are those of the author(s)
and not necessarily those of the NHS, the NIHR or the Department of Health.
Availability of data and materials
All information used in this study is available from the 23andMe website
which can be accessed at https://www.23andme.com/en-gb/health/reports.
Authors’ contributions
ML, CML, MT performed the analysis. CML conceived of the study and
participated in its design and coordination. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
As the research reported herein does not deal directly with sensitive data,
ethics approval and was not required and consent was not sought. This is in
line with UK ethics guidelines available at https://www.gov.uk/government/
publications/health-research-ethics-committees-governance-arrangements.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Medical and Molecular Genetics, King’s College London, 8th
Floor Tower Wing, Guy’s Hospital, Great Maze Pond, London SE1 9RT, UK.
2SGDP Centre, Institute of Psychiatry, Psychology & Neuroscience, King’s
College London, De Crespigny Park, Denmark Hill, London SE5 8EF, UK.
Received: 3 January 2017 Accepted: 28 May 2017
References
1. Chua EW, Kennedy MA. Current state and future prospects of direct-to-
consumer Pharmacogenetics. Front Pharmacol. 2012;3:152.
2. Rasmussen-Torvik LJ, Stallings SC, Gordon AS, Almoguera B, Basford MA,
Bielinski SJ, et al. Design and anticipated outcomes of the eMERGE-PGx
project: a multicenter pilot for preemptive pharmacogenomics in electronic
health record systems. Clin Pharmacol Ther. 2014;96:482–9.
3. Burton A. Are we ready for direct-to-consumer genetic testing? Lancet Neurol.
2015;14:138–9.
4. Dandekar S, Chang E, Hromatka B, Chubb A, Wu S. Guidelines on Vetting
and Reporting Variants with Strong Effects on Health [PDF]. 23andMe; 2014.
https://23andme.https.internapcdn.net/res/pdf/45NSStEUhM8G-e_5JXdTUw_
23-07_Vetting_Variants.pdf. Accessed 9 Dec 2016.
5. Table of Pharmacogenomic Biomarkers in Drug Labeling: U.S. Food and
Drug Administration; 2015. http://www.fda.gov/drugs/scienceresearch/
researchareas/pharmacogenetics/ucm083378.htm. Accessed 8 Dec 2016.
6. Relling M, Klein T. CPIC: clinical Pharmacogenetics implementation Consortium
of the Pharmacogenomics research network. Nature. 2011;89:464–7.
7. Drug Labels: PharmGKB; 2016. https://www.pharmgkb.org/view/drug-labels.
do. Accessed 8 Dec 2016.
8. Swen J, Nijenhuis M, Boer AD, Grandia L, AM-vd Z, Mulder H, et al.
Pharmacogenetics: from bench to byte— an update of guidelines. Clin
Pharmacol Ther. 2011;89:662–73.
9. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, et al. A
global reference for human genetic variation. Nature. 2015;526:68–74.
10. Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring
population-specific haplotype structure and linking correlated alleles of
possible functional variants. Bioinformatics. 2015;31:3555–7.
11. Johnson AD, Handsaker RE, Pulit SL, Nizzari MM, O’Donnell CJ, de Bakker PI.
SNAP: a web-based tool for identification and annotation of proxy SNPs
using HapMap. Bioinformatics. 2008;24:2938–9.
12. Dilantin® (extended phenytoin sodium capsules, USP): Parke-Davis Div of
Pfizer Inc; 1976. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/
008762s054,010151s041lbl.pdf. Accessed 8 Dec 2016.
13. Caudle KE, Rettie AE, Whirl-Carrillo M, Smith LH, Mintzer S, Lee MTM, et al.
Clinical Pharmacogenetics implementation Consortium guidelines for
CYP2C9 and HLA-B genotypes and Phenytoin dosing. Clin Pharmacol Ther.
2014;96:542–8.
14. Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. BUMC
Proceedings. 2000;13:421–3.
15. Gould DB, Phalan FC, van Mil SE, Sundberg JP, Vahedi K, Massin P, et al.
Role of COL4A1 in small-vessel disease and hemorrhagic stroke. N Engl J
med. 2006;354:1489–96.
16. Abacavir Label. 2015. http://www.accessdata.fda.gov/drugsatfda_docs/label/
2015/020977s030,020978s034lbl.pdf. Accessed 8 Dec 2016.
17. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, et al. High
sensitivity of human leukocyte antigen-b*5701 as a marker for
immunologically confirmed abacavir hypersensitivity in white and black
patients. Clin Infect Dis. 2008;46:1111–8.
18. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J, et al.
HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J med.
2008;358:568–79.
19. Martin MA, Hoffman JM, Freimuth RR, Klein TE, Dong BJ, Pirmohamed M,
et al. Clinical Pharmacogenetics implementation Consortium (CPIC)
guidelines for HLA-B genotype and Abacavir dosing: 2014 update. Clin
Pharmacol Ther. 2014;95:499–500.
20. Badulli C, Sestini R, Sbarsi I, Baroncelli M, Pizzochero C, Martinetti M, et al.
Tag SNPs of the ancestral haplotype 57.1 do not substitute HLA-B*57:01
typing for eligibility to abacavir treatment in the Italian population.
Pharmacogenomics. 2012;13:247–9.
21. Rodrıguez-Novoa S, Cuenca L, Morello J, Cordoba M, Blanco F, Jimenez-
Nacher I, et al. Use of the HCP5 single nucleotide polymorphism to predict
hypersensitivity reactions to abacavir: correlation with HLA-B*5701. J
Antimicrob Chemother. 2010;65:1567–9.
22. Melis R, Lewis T, Millson A, Lyon E, McMillin GA, Slev PR, et al. Copy number
variation and incomplete linkage disequilibrium interfere with the HCP5
genotyping assay for abacavir hypersensitivity. Genet Test Mol Biomarkers.
2012;16:1111–4.
23. Hayes CN, Imamura M, Aikata H, Chayama K. Genetics of IL28B and
HCV–response to infection and treatment. Nat rev Gastroenterol
Hepatol. 2012;9:406–17.
24. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic
variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Nature. 2009;461:399–401.
25. SNPwatch: More Evidence That Genetic Variations are Important for Hepatitis C
Infection and Treatment. 23andMe. 2009. https://blog.23andme.com/news/
snpwatch-more-evidence-that-genetic-variations-are-important-for-hepatitis-c-
infection-and-treatment/ - eh3jgCMb5xEkjrQm.99. Accessed 8 Dec 2016.
26. ABP V-K. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of
5-fluorouracil. Eur J Cancer. 2004;40:939–50.
27. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA, et al. The
clinical Pharmacogenetics implementation Consortium guideline for SLCO1B1
and Simvastatin-induced Myopathy: 2014 update. Clin Pharmacol Ther.
2014;96:423–8.
28. Amstutz U, Froehlich TK, Largiader CR. Dihydropyrimidine dehydrogenase
gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics.
2011;12:1321–36.
29. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S, et al.
Clinical relevance of different dihydropyrimidine dehydrogenase gene
single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer
Ther. 2006;5:2895–904.
Lu et al. BMC Medical Genomics  (2017) 10:47 Page 7 of 8
30. Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz
U, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>a/HapB3,
and c.1601G>a as predictors of severe fluoropyrimidine-associated toxicity: a
systematic review and meta-analysis of individual patient data. Lancet Oncol.
2015;16:1639–50.
31. Yen T, Nightingale BN, Burns JC, Sullivan DR, Stewart PM.
Butyrylcholinesterase (BCHE) genotyping for post-Succinylcholine apnea in
an Australian population. Clin Chem. 2003;49:1297–308.
32. Cui R, Kamatani Y, Takahashi A, Usami M, Hosono N, Kawaguchi T, et al.
Functional variants in ADH1B and ALDH2 coupled with alcohol and
smoking synergistically enhance esophageal cancer risk. Gastroenterology.
2009;137:1768–75.
33. Exploring the costs of unsafe care in the NHS London: Frontier Economics
Ltd; 2014. http://www.frontier-economics.com/documents/2014/10/
exploring-the-costs-of-unsafe-care-in-the-nhs-frontier-report-2-2-2-2.pdf.
Accessed 8 Dec 2016.
34. de Bakker PI, McVean G, Sabeti PC, Miretti MM, Green T, Marchini J, et al. A
high-resolution HLA and SNP haplotype map for disease association studies
in the extended human MHC. Nat Genet. 2006;38:1166–72.
35. Altar CA, Carhart JM, Allen JD, Hall-Flavin DK, Dechairo BM, Winner JG.
Clinical validity: combinatorial pharmacogenomics predicts antidepressant
responses and healthcare utilizations better than single gene phenotypes.
Pharmacogenomics J. 2015;15:443–51.
36. Numanagic I, Malikic S, Pratt VM, Skaar TC, Flockhart DA, Sahinalp SC.
Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing
data. Bioinformatics. 2015;31:i27–34.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Lu et al. BMC Medical Genomics  (2017) 10:47 Page 8 of 8
